Immutep (IMMP) Non-Current Assets (2011 - 2025)
Immutep's (IMMP) quarterly Non-Current Assets came in at $4.9 million in Q4 2025, down 13.08% YoY from $5.6 million in Q4 2024, and down 3.61% on a QoQ basis from $5.1 million in Q2 2025.
Immutep (IMMP) Non-Current Assets (2011 - 2025) Analysis & Trends
Immutep (IMMP) has 15 years of Non-Current Assets data on file, last reported at $4.9 million in Q4 2025.
- Quarterly Non-Current Assets fell 13.08% year-over-year to $4.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.9 million (down 13.08% YoY) and the FY2025 annual result came in at $5.1 million, down 25.07% from the prior year.
- Non-Current Assets eased to $4.9 million in Q4 2025, from $5.1 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $10.5 million in Q2 2021 to a low of $4.9 million in Q4 2025.
- A 5-year average of $7.2 million and a median of $7.0 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2021 — Non-Current Assets grew 3.54% — and 2025, when it fell 25.07%.
- Tracing IMMP's Non-Current Assets over 5 years: stood at $9.1 million in 2021, then retreated by 22.48% to $7.1 million in 2022, then decreased by 1.29% to $7.0 million in 2023, then decreased by 19.98% to $5.6 million in 2024, then fell by 13.08% to $4.9 million in 2025.
- The last three Non-Current Assets figures came in at $4.9 million (Q4 2025), $5.1 million (Q2 2025), and $5.6 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Immutep | 57.14 Mn | -7.95 Mn | - | 4.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.87 Mn |
| Jun 30, 2025 | 5.05 Mn |
| Dec 31, 2024 | 5.60 Mn |
| Jun 30, 2024 | 6.74 Mn |
| Dec 31, 2023 | 7.00 Mn |
| Jun 30, 2023 | 8.34 Mn |
| Dec 31, 2022 | 7.09 Mn |
| Jun 30, 2022 | 8.14 Mn |
| Dec 31, 2021 | 9.15 Mn |
| Jun 30, 2021 | 10.48 Mn |
| Dec 31, 2020 | 10.38 Mn |
| Jun 30, 2020 | 10.12 Mn |
| Dec 31, 2019 | 11.00 Mn |
| Jun 30, 2019 | 11.91 Mn |
| Dec 31, 2018 | 12.84 Mn |
| Jun 30, 2018 | 13.90 Mn |
| Jun 30, 2017 | 14.31 Mn |
| Mar 31, 2017 | 13.87 Mn |
| Jun 30, 2016 | 15.59 Mn |
| Jun 30, 2015 | 17.85 Mn |